Acquired metabolic disease
MONDO:0006504An instance of metabolic disease that is acquired during the lifetime of the individual.
Also known as: acquired metabolic disease
182 clinical trials for this condition and its sub-types, 0 tagged with Acquired metabolic disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Acquired metabolic disease
-
AL amyloidosis 92 trials · 98 incl. sub-types
2 sub-types
- Primary systemic amyloidosis 22 trials
- Primary localized amyloidosis 0 trials
-
Paroxysmal nocturnal hemoglobinuria 73 trials
2 sub-types
- Paroxysmal nocturnal hemoglobinuria 1 0 trials
- Paroxysmal nocturnal hemoglobinuria 2 0 trials
-
Acquired lipodystrophy 3 trials · 9 incl. sub-types
2 sub-types
- Acquired partial lipodystrophy 6 trials
- Acquired generalized lipodystrophy 0 trials
-
Acquired hyperprolactinemia 1 trial
2 sub-types
- Galactorrhoea-hyperprolactinaemia 0 trials
- Postpartum amenorrhea-galactorrhea syndrome 0 trials
-
Auto-brewery syndrome 1 trial
-
Acquired adrenogenital syndrome 0 trials
-
Acquired lactic acidosis 0 trials
-
Acquired mineral metabolism disease 0 trials
-
Acquired porphyria 0 trials
1 sub-type
- Sporadic porphyria cutanea tarda 0 trials
-
Acquired xanthinuria 0 trials
-
Bladder fermentation syndrome 0 trials
-
Carotenemia 0 trials
-
PNH drug iptacopan tested in Real-World setting – but study cut short
Disease control Stopped earlyThis study looked at how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) when used in everyday medical practice in Russia. Only 6 adults took part, and the study was terminated early. Researchers measured whether patients' hemoglobin levels…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Heart scan tracer may reveal Chemo's effect on amyloid buildup
Disease control Stopped earlyThis pilot study tests whether a special PET scan tracer called 18F florbetapir can detect changes in amyloid protein deposits in the heart of people with AL cardiac amyloidosis who are receiving chemotherapy. Four participants will have a PET/CT scan before starting chemotherapy…
Phase 4 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental NK cell therapy for blood cancers hits early hurdle
Disease control Stopped earlyThis early-stage study tested a new drug called SAR445514, which helps the body's natural killer (NK) cells attack cancer cells in people with multiple myeloma or light-chain amyloidosis that had returned or stopped responding to other treatments. The study was terminated early, …
Phase 1 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Experimental antibody trial for rare heart disease halted early
Disease control Stopped earlyThis phase 3 study tested an experimental drug called birtamimab in 208 people with advanced AL amyloidosis, a rare disease where abnormal proteins damage organs like the heart. Participants received either birtamimab or a placebo, plus standard chemotherapy. The goal was to see …
Phase 3 • Sponsor: Prothena Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
BCX9930 safety checked in PNH patients who benefited from treatment
Disease control Stopped earlyThis study looked at the long-term safety of BCX9930, an oral medication, for people with paroxysmal nocturnal hemoglobinuria (PNH) who had already benefited from the drug in a previous study. It included 28 participants and aimed to monitor side effects. The study was terminated…
Phase 2 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Promising drug combo for rare amyloidosis hits snag: trial ends early
Disease control Stopped earlyThis study tested a drug called ixazomib plus dexamethasone against other standard treatments for people with relapsed AL amyloidosis, a rare disease where abnormal proteins build up in organs. The trial aimed to see if the combination improved blood markers and slowed heart or k…
Phase 3 • Sponsor: Millennium Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC